Semaglutide

In December 2017, the US Food and Drug Administration (FDA) approved the listing of Smeglugan peptide injection to the auxiliary diet control and exercise to improve the blood glucose control of patients with type 2 diabetes. In addition, Novo and Nord also developed the oral dosage type Rybelsus of Smeglugin, and was first approved by FDA in September 2019. This is also the world's first approved oral GLP-1 drug. diabetes. In essence, Smeglugin is a hypoglycemic drug, but because drugs such as Smeglugin peptide can slow the stomach empty and suppress appetite, it will reduce weight.

In view of this, in June 2021, FDA officially approved the long -term weight management of obesity or overweight adults. The applicable people are: simple patients with BMI ≥30 kg/m2; and BMI> 27 kg/m2 and merge at least one obesity complication, such as hypertension, type 2 diabetes, or abnormal blood lipids. It was also this approval that the foreshadowing was buried for Smeglugin on the road of "weight loss magic medicine".

In April 2021, Smegugan was approved in China for blood sugar control for patients with type 2 diabetes (T2DM). Although the weight loss indication is not approved in China, the demand for domestic weight loss cannot be held in China. In addition, the main theme of "thinness with thinness", in the second half of 2022, Smeglugin peptide "did not approve" in the field of weight loss. , Once on multiple e -commerce platforms, it has set off a boom in buying, and once became a high -priced "out of stock king", which directly led to the problems of manufacturers' production and supply. Nuo and Nord's July last year said Resumption of drug supply will stop the supply of off -hospital markets.

The popularity of Smegugu peptide has also been confirmed from Nuo and Nord's financial data. According to the recent 2022 results announced by Nuo and Nord, the annual revenue of Nuo and Nord's GLP-1 business was 83.371 billion Dan Ying Crown (equivalent to about 81.6 billion yuan), an increase of 56%year-on-year. Among them, Smeglugin's sales were 59.75 billion Dan Ying Crown (equivalent to about 58.5 billion yuan), an increase of 77%year -on -year. The sales performance of GLP-1 products in the field of type 2 diabetes therapy in China has increased by 102%in Dan Ying Krone.

Of course, the explosion of Smeglugin in the field of weight loss is closely related to its significant effect. "It is time to eat, drink and drink, take 5 pounds of weight, lose 30 pounds in January" and so on. In addition, "lying flat" can be thinner, which has attracted countless eyes to Smegtu peptides, once known as "weight loss magic medicine". However, some clinicians have stated that Simei Gulu peptide has more than 2/3 of the domestic sales in China to lose weight, not diabetes. On the one hand In terms of Smeglugan peptide as a prescription drug, there are hidden dangers in the safety of superpatient drugs.

It is worth noting that the domestic research conclusions of such drugs stem from large -scale adult obesity patients. For people with slightly fat or even normal weight (BM <27kg/m2), benefits and possible risks are still unknown. In addition, in addition to the hypoglycemia reactions that are hypogenal drugs that occur in hypoglycemic drugs, the gastrointestinal reactions are prominent, and the incidence of nausea, constipation, vomiting and diarrhea is as high as 82.8%. 7%. The most important thing is that Smeglugin has not been approved for weight loss indications in China. The problem of medication channels and drug use of such people is worthy of attention.